Blog Layout

Exercise and Cancer
October 26, 2020

Patients with a malignancy, and in particular those receiving treatment for a malignancy, often experience fatigue. And while adequate rest is important, there has been increasing evidence over the past few years that a regular exercise programme can have a considerable benefit on this fatigue, as well and many other treatment related side effects.

The Clinical Oncology Society of Australia (COSA) released a position statement in 2018, which was been updated in April 2020, clarifying the role of exercise in cancer care. It suggests that exercise be “embedded as part of standard practice in cancer care” and that it be “viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment”. The statement goes further to recommend:


  • At least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic exercise each week; and
  • Two to three resistance exercise (ie. lifting weights) sessions each week involving moderate to vigorous-intensity exercises targeting the major muscle groups.1


 Moderate-intensity exercise refers to exercise that requires a moderate amount of effort, and noticeably accelerates the heart rate, such as walking, cycling, or swimming at a ‘somewhat hard’ pace. Vigorous-intensity exercise is perceived as ‘hard to very hard’, such as running, or cycling / swimming at a hard pace. During vigorous exercise, you would expect to be a little breathless, and unable to talk in full sentences.


For many with a cancer diagnosis, these targets may seem optimistic, or even unrealistic, and certainly exercise plans need to be tailored to an individual’s abilities and health status. For this reason, accredited exercise physiologists or physiotherapist are well-placed to guide and prescribe an appropriate programme.


The proven benefits of an exercise regimen in those receiving treatments for a malignancy are multiple. Evidence suggests regular exercise improves physical functioning, reduces cancer or treatment related fatigue, alleviates psychological distress, and improves quality of life. 2 This is, of course, in addition to other well establish benefits of improving cardiovascular health, and preventing conditions such as cardiovascular disease and osteoporosis. There is also evolving epidemiological research suggesting that exercise may have an impact on reducing cancer recurrence. Further research is being undertaken to evaluate the impact of exercise on cancer-related survival.


The year 2020 has proven challenging in many ways, including barriers to maintaining an exercise regimen through gym and pool closures, and lockdown orders. But with the gradual relaxation of restrictions, and the weather warming, the opportunities are increasing.


Consider talking with your doctor / oncologist to arrange referral to an appropriate exercise specialist.  


Dr Heather Francis

Ballarat Cancer Care & Haematology


1 https://www.cosa.org.au/media/332637/cosa-exercise-position-statement-april-2020-1.pdf


2 Cormie, P., et al., The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev, 2017. 39(1): p.71-92.

Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
February 16, 2025
Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
December 3, 2024
We are pleased to announce palliative care physician Dr Russell Pearce will be joining our team in February 2025.
New haematologist  joining the Ballarat Cancer Care team
August 27, 2024
We are excited to announce Dr Tishya Indran will be joining our team as of 18th September 2024. 
4th Dose COVID-19 Vaccine for Immunocompromised Patients
March 1, 2022
The Australian Technical Advisory Group on Immunisation (ATAGI) has approved a fourth dose of a COVID-19 vaccine for people with weakened immune systems. People aged 18 years or older with weakened immune system who received a 3-dose primary course of the COVID-19 vaccine are now recommended to receive the fourth dose ≥ 3 months after their third dose. This is expected to improve protection against symptomatic infection, serious illness, or death from COVID-19 infection.
COVID-19 Vaccine Booster Shots In Our Patients With Cancer
November 8, 2021
The Government and the Medical advisory group (ATAGI) have release new recommendations last week for individuals who are severely immunocompromised in regards to the COVID-19 vaccine. These recommendations will affect some (but not all) of our patients. As always, we are happy to discuss any of the recommendations further with all of our patients.
COVID-19 Vaccination FAQs July 2021
July 20, 2021
In the last few months, I have been inundated with many questions regarding COVID-19 vaccination and blood clots from patients and other health practitioners. In this article, I have compiled these frequently asked questions.
New PBS listings!
July 2, 2021
Despite a global pandemic, new data relating to oncology treatments continues to be published, and it seems that this is increasingly translating into improved drug access here in Australia.
Astra Zeneca (AZ) vaccine safety information
March 26, 2021
In light of recent reports of clotting events following Astra Zeneca (AZ) vaccine in Europe - we have been frequently asked questions regarding the safety of AZ vaccine in patients with previous clot events and/or blood problems
February 25, 2021
Two vaccines against the coronavirus have now been approved for use in Australia, role-out of the vaccine begins this week in high-risk populations.
January 18, 2021
Dr Swe Myo Htet Consultant Haematologist MBBS, FRACP, FRCPA, MRCP
More Posts
Share by: